代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用

doi:10.6040/j.issn.1673-3770.0.2024.573

摘要/Abstract

摘要： 目的探讨循环代谢特征作为预测糖尿病性黄斑水肿(diabetic macular edema, DME)患者雷珠单抗治疗反应的预后因素。方法本研究为观察性临床研究,纳入46例确诊为累及中央凹的DME患者［基线中央视网膜厚度(central retinal thickness, CRT)］ ≥320 μm,均接受3个月雷珠单抗玻璃体内注射治疗。治疗前及治疗后3个月后分别评估CRT和最佳矫正视力(best corrected visual acuity, BCVA)。并检测治疗前(基线)血液中糖代谢、胱氨酸代谢和肌酸代谢等代谢指标,经单因素分析筛选后,采用多因素Logistic回归分析(调整年龄、性别等混杂因素)探究代谢指标与CRT和BCVA治疗反应的关联。结果治疗3个月后,CRT从(568.20±103.30)μm显著降低至(453.60±03.30)μm(P=0.000 4),BCVA 从(0.90±0.56)改善至(0.69±0.54)(P<0.000 1)。对全身因素和临床结果的分析显示,糖代谢相关指标(丙酮酸P=0.020 0、乳酸P=0.010 3、葡萄糖P=0.005 1、糖化血红蛋白P=0.005 3)及肌酸代谢相关的肌酐(P=0.031 8)水平与 CRT 的改善存在显著负相关。此外,对全身因素和视力预后的分析结果显示,乳酸(P=0.030 0)、葡萄糖(P=0.028 3)、糖化血红蛋白(P=0.013 9)和胱氨酸代谢相关的胱抑素(P=0.019 7)水平与BCVA的改善也呈显著负相关。多因素logistic回归分析进一步证实:糖代谢指标［葡萄糖比值比(Odds Ratio, OR)=1.66,糖化血红蛋白OR=1.71,乳酸OR=2.19］及肌酐(OR=1.02)独立预测CRT改善(均P<0.05);胱抑素(OR=8.55)联合糖代谢指标(葡萄糖OR=1.42,糖化血红蛋白OR=1.64,乳酸OR=1.91)独立预测BCVA改善(均P<0.05)。结论 DME患者循环代谢特征,特别是糖代谢、肌酸代谢和胱氨酸代谢相关指标,能够有效预测雷珠单抗治疗反应,为临床提供潜在的生物标志物。

关键词: 糖尿病性黄斑水肿, 糖尿病视网膜病变, 雷珠单抗, 代谢特征, 临床疗效, 生物标志物

Abstract: Objective To investigate the prognostic value of circulatory metabolic characteristics as predictors of treatment response to ranibizumab in patients with diabetic macular edema(DME). Methods This study was an observational clinical trial involving 46 patients diagnosed with DME involving the central fovea ［baseline central retinal thickness(CRT)≥320 μm］. All participants received intravitreal injections of ranibizumab for 3 months. CRT and best-corrected visual acuity(BCVA)were assessed at baseline and 3 months post-treatment. Baseline blood levels of metabolic markers related to glucose metabolism, cysteine metabolism, and creatine metabolism were measured. Univariate analyses were first performed to screen candidate variables, and then multivariate logistic regression analyses(adjusted for confounding factors such as age and sex)were conducted to investigate the associations between baseline metabolic markers and anatomical(CRT)and functional(BCVA)treatment responses. Results After 3 months of treatment, CRT significantly decreased from(568.20±103.30)μm to(453.6±103.30 )μm(P=0.000 4), and BCVA improved from 0.90±0.56 to 0.69±0.54(P<0.000 1). Analysis of systemic factors and clinical outcomes revealed significant negative correlations between glucose metabolism-related indicators(pyruvate, P=0.020 0; lactate, P=0.010 3; glucose, P=0.005 1; glycated hemoglobin, P=0.005 3)and CRT improvement. Additionally, creatinine levels related to creatine metabolism(P=0.031 8)were significantly negatively correlated with CRT improvement. Further analysis of systemic factors and visual prognosis showed significant negative correlations between lactate(P=0.030 0), glucose(P=0.028 3), glycated hemoglobin(P=0.013 9), and cysteine metabolism-related cystatin(P=0.019 7)with BCVA improvement. Multivariate logistic regression analysis further confirmed that glucose metabolism markers ［glucose odds ratio(OR)=1.66, HbA1c OR=1.71, lactate OR=2.19］ and creatinine(OR=1.02)independently predicted CRT improvement(all P<0.05), cystatin C(OR=8.55)combined with glucose metabolism indicators(glucose OR=1.42, HbA1c OR=1.64, lactate OR=1.91)independently predicted improvements in BCVA(all P<0.05). Conclusion Circulating metabolic characteristics in DME patients, particularly indicators related to glucose metabolism, creatine metabolism, and cysteine metabolism, can effectively predict the response to ranibizumab treatment, providing potential biomarkers for clinical practice.

Key words: Diabetic macular edema, Diabetic retinopathy, Ranibizumab, Metabolic characteristics, Clinical efficacy, Biomarkers

中图分类号:

R739.62

孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.

SUN Qingzhu, SHEN Jian, CHEN Xing, WU Yanbing, ZENG Lun. The role of metabolic indicators in predicting ranibizumab efficacy in diabetic macular edema[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 74-81.

参考文献 38

[1]	Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of diabetic retinopathy in the US in 2021[J]. JAMA Ophthalmol, 2023, 141(8): 747-754. doi: 10.1001/jamaophthalmol.2023.2289
[2]	Gonzalez-Cortes JH, Martinez-Pacheco VA, Gonzalez-Cantu JE, et al. Current treatments and innovations in diabetic retinopathy and diabetic macular edema[J]. Pharmaceutics, 2022, 15(1): 122. doi: 10.3390/pharmaceutics15010122
[3]	Association AD. 11. microvascular complications and foot care: Standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(1): S151-S167. doi: 10.2337/dc21-S011
[4]	Tomkins-Netzer O, Niederer R, Lightman S. The role of statins in diabetic retinopathy[J]. Trends Cardiovasc Med, 2024, 34(2): 128-135. doi: 10.1016/j.tcm.2022.11.003
[5]	ElSayed NA, Aleppo G, Aroda VR, et al. Erratum. 2. classification and diagnosis of diabetes: Standards of care in diabetes: 2023. diabetes care 2023;46(suppl. 1): S19-S40[J]. Diabetes Care, 2023, 46(5): 1106. doi: 10.2337/dc23-s002
[6]	Tatsumi T. Current treatments for diabetic macular edema[J]. Int J Mol Sci, 2023, 24(11): 9591. doi: 10.3390/ijms24119591
[7]	Szeto SK, Lai TY, Vujosevic S, et al. Optical coherence tomography in the management of diabetic macular oedema[J]. Prog Retin Eye Res, 2024, 98: 101220. doi: 10.1016/j.preteyeres.2023.101220
[8]	Gabrielle PH, Mehta H, Barthelmes D, et al. From randomised controlled trials to real-world data: clinical evidence to guide management of diabetic macular oedema[J]. Prog Retin Eye Res, 2023, 97: 101219. doi: 10.1016/j.preteyeres.2023.101219
[9]	Ehlers JP, Yeh S, Maguire MG, et al. Intravitreal pharmacotherapies for diabetic macular edema: a report by the American academy of ophthalmology[J]. Ophthalmology, 2022, 129(1): 88-99. doi: 10.1016/j.ophtha.2021.07.009
[10]	Virgili G, Curran K, Lucenteforte E, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis[J]. Cochrane Database Syst Rev, 2023, 2023(6): CD007419. doi: 10.1002/14651858.CD007419.pub7
[11]	Lin TW, Chien Y, Lin YY, et al. Establishing liposome-immobilized dexamethasone-releasing PDMS membrane for the cultivation of retinal pigment epithelial cells and suppression of neovascularization[J]. Int J Mol Sci, 2019, 20(2): 241. doi: 10.3390/ijms20020241
[12]	Sharma D, Zachary I, Jia HY. Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases[J]. Invest Ophthalmol Vis Sci, 2023, 64(5): 28. doi: 10.1167/iovs.64.5.28
[13]	Wang ZY, Yang FY, Cai SW, et al. Plasma metabolomic profiling of diabetic macular edema[J]. Sci Rep, 2025, 15(1): 10012. doi: 10.1038/s41598-025-94759-8
[14]	Wang HY, Fang JW, Chen FG, et al. Metabolomic profile of diabetic retinopathy: a GC-TOFMS-based approach using vitreous and aqueous humor[J]. Acta Diabetol, 2020, 57(1): 41-51. doi: 10.1007/s00592-019-01363-0
[15]	Du XH, Yang L, Kong L, et al. Metabolomics of various samples advancing biomarker discovery and pathogenesis elucidation for diabetic retinopathy[J]. Front Endocrinol(Lausanne), 2022, 13: 1037164. doi: 10.3389/fendo.2022.1037164
[16]	Welsh P, Rankin N, Li Q, et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial[J]. Diabetologia, 2018, 61(7): 1581-1591. doi: 10.1007/s00125-018-4619-x
[17]	Lin HT, Cheng ML, Lo CJ, et al. 1H nuclear magnetic resonance(NMR)-based cerebrospinal fluid and plasma metabolomic analysis in type 2 diabetic patients and risk prediction for diabetic microangiopathy[J]. J Clin Med, 2019, 8(6): 874. doi: 10.3390/jcm8060874
[18]	Sun Y, Zou HL, Li XJ, et al. Plasma metabolomics reveals metabolic profiling for diabetic retinopathy and disease progression[J]. Front Endocrinol(Lausanne), 2021, 12: 757088. doi: 10.3389/fendo.2021.757088
[19]	Liew G, Lei Z, Tan G, et al. Metabolomics of diabetic retinopathy[J]. Curr Diab Rep, 2017, 17(11): 102. doi: 10.1007/s11892-017-0939-3
[20]	Zuo JJ, Lan Y, Hu HL, et al. Metabolomics-based multidimensional network biomarkers for diabetic retinopathy identification in patients with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2021, 9(1): e001443. doi: 10.1136/bmjdrc-2020-001443
[21]	Lu W, Xiao K, Zhang X, et al. A machine learning model for predicting anatomical response to Anti-VEGF therapy in diabetic macular edema. Front Cell Dev Biol, 2025, 13: 1603958. doi: 10.3389/fcell.2025.1603958
[22]	Wang P, Hu Z, Hou M, et al. Relationship between macular thickness and visual acuity in the treatment of diabetic macular edema with anti-VEGF therapy: systematic review. J Vitreoretin Dis, 2023, 7(1): 57-64. doi:10.1177/24741264221138722
[23]	Li MM, Shao JJ, Guo ZJ, et al. Novel mitochondrion-targeting copper(II)complex induces HK2 malfunction and inhibits glycolysis via Drp1-mediating mitophagy in HCC[J]. J Cell Mol Med, 2020, 24(5): 3091-3107. doi: 10.1111/jcmm.14971
[24]	Jian QZ, Wu YJ, Zhang F. Metabolomics in diabetic retinopathy: from potential biomarkers to molecular basis of oxidative stress[J]. Cells, 2022, 11(19): 3005. doi: 10.3390/cells11193005
[25]	Kieran NW, Suresh R, Dorion MF, et al. microRNA-210 regulates the metabolic and inflammatory status of primary human astrocytes[J]. J Neuroinflammation, 2022, 19(1): 10. doi: 10.1186/s12974-021-02373-y
[26]	Xu YX, Pu SD, Zhang YT, et al. Insulin resistance is associated with the presence and severity of retinopathy in patients with type 2 diabetes[J]. Clin Exp Ophthalmol, 2024, 52(1): 63-77. doi: 10.1111/ceo.14344
[27]	Jensen ET, Rigdon J, Rezaei KA, et al. Prevalence, progression, and modifiable risk factors for diabetic retinopathy in youth and young adults with youth-onset type 1 and type 2 diabetes: the SEARCH for diabetes in youth study[J]. Diabetes Care, 2023, 46(6): 1252-1260. doi: 10.2337/dc22-2503
[28]	Suzuki Y, Kiyosawa M. Relationship between diabetic nephropathy and development of diabetic macular edema in addition to diabetic retinopathy[J]. Biomedicines, 2023, 11(5): 1502. doi: 10.3390/biomedicines11051502
[29]	Fan YM, Tan X, Zhao HC, et al. Cysteine metabolism in tumor redox homeostasis[J]. Curr Med Chem, 2023, 30(16): 1813-1823. doi: 10.2174/0929867329666220817141227
[30]	Yoon SJ, Combs JA, Falzone A, et al. Comprehensive metabolic tracing reveals the origin and catabolism of cysteine in mammalian tissues and tumors[J]. Cancer Res, 2023, 83(9): 1426-1442. doi: 10.1158/0008-5472.CAN-22-3000
[31]	Feng BY, Lu Y, Ye L, et al. Mendelian randomization study supports the causal association between serum cystatin C and risk of diabetic nephropathy[J]. Front Endocrinol(Lausanne), 2022, 13: 1043174. doi: 10.3389/fendo.2022.1043174
[32]	Han RY, Gong RW, Liu W, et al. Proteome changes associated with the VEGFR pathway and immune system in diabetic macular edema patients at different diabetic retinopathy stages[J]. Curr Eye Res, 2022, 47(7): 1050-1060. doi: 10.1080/02713683.2022.2068181
[33]	涂晶, 彭玉惠. 肾功能相关指标与糖尿病视网膜病变的相关性[J]. 中国医学工程, 2023, 31(10):29-33. doi: 10.19338/j.issn.1672-2019.2023.10.007 TU Jing, PENG Yuhui. Correlation of renal function related indicators and diabetic retinopathy in patients[J]. China Medical Engineering, 2023, 31(10):29-33. doi: 10.19338/j.issn.1672-2019.2023.10.007
[34]	Wang DN, Fan KW, He ZP, et al. The relationship between renal function and diabetic retinopathy in patients with type 2 diabetes: a three-year prospective study[J]. Heliyon, 2023, 9(4): e14662. doi: 10.1016/j.heliyon.2023.e14662
[35]	Sun Y, Kong L, Zhang AH, et al. A hypothesis from metabolomics analysis of diabetic retinopathy: arginine-creatine metabolic pathway may be a new treatment strategy for diabetic retinopathy[J]. Front Endocrinol(Lausanne), 2022, 13: 858012. doi: 10.3389/fendo.2022.858012
[36]	Khoja S, Lambert J, Nitzahn M, et al. Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities[J]. Mol Ther Methods Clin Dev, 2022, 25: 278-296. doi: 10.1016/j.omtm.2022.03.015
[37]	Apuzzo A, Gravina S, Panozzo G, et al. From diagnosis to prognosis: a paradigm shift for multimodal imaging in assessing diabetic macular edema[J]. Eur J Ophthalmol, 2024, 34(1): 7-10. doi: 10.1177/11206721231199149
[38]	Parravano M, Cennamo G, Di Antonio L, et al. Multimodal imaging in diabetic retinopathy and macular edema: an update about biomarkers[J]. Surv Ophthalmol, 2024, 69(6): 893-904. doi: 10.1016/j.survophthal.2024.06.006

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed